The NeuralBot when used with Lucid M1 System is a medical ultrasound device which assists the user in the setup and acquisition of cerebral blood flow velocity via the patient's temporal windows. It is intended for use as an adjunct to standard clinical practices for measuring and displaying cerebral blood flow velocity and the occurrence of transient emboli within the blood stream.

The NeuralBot is intended to be used by healthcare professionals qualified by training in its safe and effective use. The device is not intended to replace other means of evaluating vital patient physiological processes, is not intended to be used in fetal applications, and is not intended to be used inside the sterile field.

Device Description

The NeuralBot System is a cart mounted. robotic transcranial Doppler (TCD) probe positioning accessory for the previously cleared Lucid M1 System (K160442) which assists the user in the acquisition of cerebral blood flow velocity (CBFV) data via the patient's temporal acoustic windows.

The NeuralBot System consists of the following three subsystems mounted on a cart

1. Accessory Control Unit (ACU)
- The main accessory software including the, TCD signal search algorithm, and a. graphical user interface are installed on this subsystem.
1. Robotic Control Unit (RCU)
- Contains the electronics and embedded software that control the robotic actuators of a. the patient headmount unit.
1. Patient Headmount Unit (PHU)
- Comprised of the patient head interface, 2 MHz transducers, and the robotic probe a. positioning mechanism.

The NeuralBot System guides the operator in positioning the transducers in the PHU, one on each side of a patient's head, at their temporal regions. The 2 MHz transducers used in the NeuralBot System are the same transducers previously cleared for use with the Lucid M1 System (K160442). The NeuralBot System's probe positioning is accomplished using robotic actuators that adjust the translational and angular position of each transducer independently using TCD signal search algorithms. The accessory is designed to locate TCD signals at depths between 45 and 60 mm allowing the operator to monitor the CBFV of the vessels via the patient's temporal acoustic windows. The NeuralBot System identifies several candidate TCD signals and displays multiple signals from each side of the patient's head. At the end of the search, the NeuralBot System will then retrieve and track the best located signal.

AI/ML Overview

The NeuralBot System is a robotic transcranial Doppler (TCD) probe positioning accessory that works with the existing Lucid M1 System. It assists users in acquiring cerebral blood flow velocity (CBFV) data by guiding the positioning of transducers at the patient's temporal acoustic windows.

Here's an analysis of the acceptance criteria and supporting studies as described in the provided text:

1. Table of Acceptance Criteria and Reported Device Performance

The provided 510(k) summary does not contain a specific table detailing acceptance criteria for performance metrics (e.g., sensitivity, specificity, accuracy) related to the device's primary function of assisting in TCD signal acquisition and tracking. Instead, it focuses on general safety, effectiveness, and substantial equivalence to predicate devices, adhering to recognized standards.

Category	Acceptance Criteria (Implied)	Reported Device Performance
Safety and Effectiveness	Substantially equivalent to predicate devices with no new questions of safety and effectiveness.	"The NeuralBot System is substantially equivalent to the predicate devices.""There are no new questions of safety and effectiveness concerning the NeuralBot System.""The NeuralBot System is designed to be as safe and effective as the predicate devices."
Performance (General)	Designed to perform as well as the predicate devices.	"The NeuralBot System is designed to perform as well as the predicate devices."
Acoustic Output	Conformance to NEMA Standards Publication UD 2-2004(R2009) and UD 3-2004(R2009).	Evaluated for acoustic output per applicable sections of NEMA Standards Publication UD 2-2004(R2009) and UD 3-2004(R2009). (No specific metrics provided in the summary, reliance is on conformance to standards.)
Biocompatibility	Conformance to ISO 10993-1:2010.	Evaluated for biocompatibility per ISO 10993-1:2010. (No specific metrics provided in the summary, reliance is on conformance to standards.)
Thermal, Mechanical, Electromagnetic Safety	Conformance to IEC 60601-1, IEC 60601-1-2, and IEC 60601-2-37.	Non-clinical testing conducted per FDA Guidance using applicable sections of IEC 60601-1:2012, IEC 60601-1-2:2014, and IEC 60601-2-37:2015. (No specific metrics provided in the summary, reliance is on conformance to standards.)

2. Sample Size Used for the Test Set and Data Provenance

The document does not specify a sample size for a "test set" in the context of clinical performance or algorithm evaluation. The non-clinical testing mentioned focuses on engineering verification and validation against recognized standards for safety and electrical performance. There is no mention of data provenance (e.g., country of origin, retrospective/prospective) for a performance test set.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

Not applicable. The provided document does not describe a study involving expert-established ground truth for a test set related to diagnostic performance. The document focuses on the device's ability to assist in TCD signal acquisition and tracking, rather than providing a diagnostic interpretation.

4. Adjudication Method for the Test Set

Not applicable. There is no mention of a clinical test set requiring ground truth adjudication.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, If So, What Was the Effect Size of How Much Human Readers Improve with AI vs. Without AI Assistance

No, a multi-reader multi-case (MRMC) comparative effectiveness study comparing human readers with and without AI assistance is not described in the provided document. The NeuralBot System is presented as an accessory that assists in probe positioning and TCD signal acquisition, not as an AI interpretation tool.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

The document describes the NeuralBot System as having a "TCD signal search algorithm" and "robotic actuators that adjust the translational and angular position of each transducer independently using TCD signal search algorithms." While an algorithm is at the core of its functionality, the device is explicitly designed as an accessory that "assists the user." Therefore, its performance is inherently tied to a human-in-the-loop interaction for TCD data acquisition, and a standalone algorithm-only performance study (in the sense of diagnostic interpretation without human input) is not discussed. The "device performance" relies on its ability to guide the operator and retrieve and track the best located signal.

7. The Type of Ground Truth Used (Expert Consensus, Pathology, Outcomes Data, etc.)

The document does not describe a clinical study where ground truth of the type "expert consensus, pathology, or outcomes data" would be used. The "ground truth" implied for the device's functionality would be objective measures of its ability to locate and track TCD signals effectively, likely against established TCD methodologies or physical phantoms, but this level of detail is not provided.

8. The Sample Size for the Training Set

The document does not specify a sample size for a training set. If the "TCD signal search algorithm" utilizes machine learning, the details of its training are not included in this summary.

9. How the Ground Truth for the Training Set Was Established

The document does not provide information on how ground truth for any potential training set was established.

Summary

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo includes the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.

May 22, 2018

Neural Analytics, Inc. % Javad Seyedzadeh Cheif QA/RA 2440 S. Sepulveda Blvd., Suite 115 LOS ANGELES CA 90064

Re: K180455

Trade/Device Name: NeuralBot Regulation Number: 21 CFR 892.1550 Regulation Name: Ultrasonic pulsed doppler imaging system Regulatory Class: II Product Code: IYN, ITX, OQQ Dated: April 17, 2018 Received: April 19, 2018

Dear Javad Seyedzadeh:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{1}------------------------------------------------

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice

(https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Michael D. O'Hara For

Robert Ochs, Ph.D. Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

{3}------------------------------------------------

Image /page/3/Picture/0 description: The image contains the logo for Neural Analytics. The logo consists of two large blue letters, 'N' and 'A', stacked on top of each other. Below the letters, the words 'NEURAL ANALYTICS' are written in smaller blue font, with a thin blue line underneath.

510(k) Summary

Date Prepared	February 16, 2018
Manufacturer	Neural Analytics, Inc.2440 S Sepulveda Blvd, Suite 115Los Angeles, CA 90064Phone: (914) 473-1678Facsimile: (877) 638-7251Internal Contact: Javad SeyedzadehEmail: javad@neuralanalytics.com
OfficialCorrespondent	Javad SeyedzadehChief of QA/RA(914) 473-1678javad@neuralanalytics.com
Trade Name	NeuralBot
Common Name(s)	NeuralBot System,NeuralBot Guided Headmount Accessory,NeuralBot Guided Headmount Accessory for the Lucid M1 System
Project Name	Apollo Beta
Model Number(s)	NA-RBT-1 NeuralBotNA-DSP2 NeuralBot Procedural Set
Federal RegulationNumber	21 CFR 892.155021 CFR 892.1570
Product Codes	IYN, ITX, OQQ
Class	Class II Device

{4}------------------------------------------------

Image /page/4/Picture/0 description: The image contains the logo for Neural Analytics. The logo consists of two large blue letters, 'N' and 'A', stacked on top of each other. Below the letters, the words 'NEURAL ANALYTICS' are written in smaller, blue font. The logo is simple and modern, with a focus on the company's name.

Predicate Devices	K122710
	Shenzhen Delicate Electronics Co., Ltd.
	Transcranial Doppler with Robotic Probe Headband, EMS-9UA
	Class II
	21 CFR 892.1550, IYN
	21 CFR 892.1570, ITX and OQQ

	K160442
	NEURAL ANALYTICS, INC.
	Lucid M1 Transcranial Doppler Ultrasound System (Lucid M1 System) With 2MHz Transducers
	Class II
	21 CFR 892.1550, IYN
	21 CFR 892.1570, ITX
Performance Standards	There are no required performance standards under the Federal Food, Drug and Cosmetic Act. Voluntary standards to which we will conform include: IEC 60601-1, IEC 60601-1-2, IEC, IEC 60601-2-37, IEC 62133 (RCU rechargeable battery and ACU internal battery), ISO 10993-1, and ISO 62304.
Special Controls	There are no special controls as a special report is no longer required. The guidance referenced is “Guidance for Industry and FDA Staff - Information for Manufacturers Seeking Marketing Clearance of Diagnostic Ultrasound Systems and Transducers” dated September 9, 2008.

{5}------------------------------------------------

Image /page/5/Picture/1 description: The image shows a logo for Neural Analytics. The logo consists of two large blue letters, "N" and "A", stacked on top of each other. Below the letters, in smaller blue font, is the text "NEURAL ANALYTICS". The letters are bold and stylized, with the "N" slightly overlapping the "A".

Submission Focus:

The submission will focus on the NeuralBot System. The NeuralBot System consists of the following elements:

. Accessory Control Unit (ACU)
Robotic Control Unit (RCU)
Patient Headmount Unit (PHU)
. Cart

This system connects to the Lucid M1 System as an accessory.

Information from the Lucid M1 System (K160442) is provided in this submission for the purpose of clarification where deemed appropriate.

Device Description

The NeuralBot System consists of the following three subsystems mounted on a cart

1. Accessory Control Unit (ACU)
- The main accessory software including the, TCD signal search algorithm, and a. graphical user interface are installed on this subsystem.
1. Robotic Control Unit (RCU)
- Contains the electronics and embedded software that control the robotic actuators of a. the patient headmount unit.
1. Patient Headmount Unit (PHU)
- Comprised of the patient head interface, 2 MHz transducers, and the robotic probe a. positioning mechanism.

{6}------------------------------------------------

Image /page/6/Picture/0 description: The image shows the logo for Neural Analytics. The logo consists of two large blue letters, 'N' and 'A', stacked on top of each other. Below the letters, in smaller blue font, is the text 'NEURAL ANALYTICS'. A thin blue line underlines the text.

Communication between the Lucid M1 System (K160442) and the NeuralBot System occurs via a USB to Ethernet cable that connects the ACU to the Lucid M1 System using its digital streaming feature. The 2 MHz transducers of the PHU are connected to the Lucid M1 System's TCD probe connections (K160442).

Indications for Use

Equivalence Discussion:

The NeuralBot System and Lucid M1 System (K160442):

A full comparison of the technological characteristics of the NeuralBot System when connected to the Lucid M1 System and the Lucid M1 System was made. Both are TCD ultrasound flow systems with monitoring functions. Both systems monitor cerebral blood flow velocity and the occurrence of transient emboli within the blood stream via the temporal windows.

Both systems have equivalent modes and use pulsed wave Doppler (PWD) using color M-Mode for location of the vessel of interest.

Additionally, both devices:

Are transcranial Doppler ultrasound systems used for cerebral blood flow analysis
Monitor the cerebral blood flow velocity and the occurrence of transient emboli within ● the blood stream via the temporal windows
Utilize two transducers which are attached via a headset for cephalic monitoring
Use substantially equivalent operating modes ●
Measure equivalent hemodynamic indices
Have equivalent monitoring functions ●
Transducers are substantially equivalent
Are manufactured to meet applicable physical, mechanical, and electrical safety requirements
. Display TIC, velocity spectrum, M-Mode, velocity envelope, Mean velocity, Minimum velocity, Maximum velocity, Pulsatility index, and emboli count (in emboli and bubble exams of the Lucid M1 System)

{7}------------------------------------------------

Image /page/7/Picture/0 description: The image shows the logo for Neural Analytics. The logo consists of two large, blue letters "N" and "A" that are connected at the top. Below the letters, the words "NEURAL ANALYTICS" are written in a smaller, blue font, with a horizontal line above the words.

The NeuralBot System and the Transcranial Doppler with Robotic Probe Headband, EMS-9UA (K122710):

A full comparison of the technological characteristics of the NeuralBot System when connected to the Lucid M1 System and the Transcranial Doppler with Robotic Headband was made. Both are Robotic Probe systems intended for obtaining the information of CBFV by using a noninvasive ultrasonic technique. This method of measurement is particularly useful for examining the major arteries supplying blood to the brain via the temporal window.

Both systems have equivalent modes and use pulsed wave Doppler (PWD) using color M-Mode for location of the vessel of interest. Both systems can automatically adjust the position of the ultrasonic transducers during monitoring according to the signal intensity of CBFV via the patient's temporal windows.

Summary of Non-Clinical Testing and Reliance on Standards

The NeuralBot System when used with the Lucid M1 system is evaluated for acoustic output, biocompatibility, and accuracy, as well as thermal, electromagnetic, and mechanical safety. Non-clinical testing to support thermal, mechanical, electromagnetic, and mechanical safety is conducted per the FDA Guidance Information for Manufacturers Seeking Marketing Clearance of Diagnostic Ultrasound Systems and Transducers, using applicable sections of the following voluntary standards:

IEC 60601-1:2012 Medical electrical equipment - Part 1: General requirements for basic safety and essential performance, Edition 3.1
. IEC 60601-1-2:2014 Medical electrical equipment - Part 1-2: General requirements for basic safety and essential performance - Collateral Standard: Electromagnetic disturbances - Requirements and tests, Edition 3.1
IEC 60601-2-37:2015 Medical electrical equipment Part 2-37: Particular requirements . for the basic safety and essential performance of ultrasonic medical diagnostic and monitoring equipment, Edition 2.1
. NEMA Standards Publication UD 2-2004(R2009) Acoustic Output Measurement Standard For Diagnostic Ultrasound Equipment Revision 3
. NEMA Standards Publication UD 3-2004(R2009) Standard for Real-Time Display of Thermal and Mechanical Acoustic Output Indices on Diagnostic Ultrasound Equipment Revision 2
ISO 10993-1:2010 Biological evaluation of medical devices -- Part 1: Evaluation and ● testing within a risk management process, Fourth Edition

{8}------------------------------------------------

Image /page/8/Picture/1 description: The image shows the logo for Neural Analytics. The logo consists of the letters "NA" in a large, bold, sans-serif font, stacked on top of each other. The letters are in blue. Below the letters, the words "NEURAL ANALYTICS" are written in a smaller, sans-serif font, also in blue.

Conclusion

The documentation provided demonstrates that:

The NeuralBot System is substantially equivalent to the predicate devices. ●
. There are no new questions of safety and effectiveness concerning the NeuralBot System.
The NeuralBot System is designed to be as safe and effective as the predicate devices.
The NeuralBot System is designed to perform as well as the predicate devices. ●

Accordingly, the NeuralBot System is believed to be substantially equivalent to the predicate devices of the same type which are lawfully distributed in interstate commerce in the United States.

Regulation Number and Section

§ 892.1550 Ultrasonic pulsed doppler imaging system.

(a)
Identification. An ultrasonic pulsed doppler imaging system is a device that combines the features of continuous wave doppler-effect technology with pulsed-echo effect technology and is intended to determine stationary body tissue characteristics, such as depth or location of tissue interfaces or dynamic tissue characteristics such as velocity of blood or tissue motion. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II.